Reuters logo
BRIEF-Amgen and AbbVie agree to settlement allowing commercialization of Amgevita
September 28, 2017 / 12:13 PM / 3 months ago

BRIEF-Amgen and AbbVie agree to settlement allowing commercialization of Amgevita

Sept 28 (Reuters) - Amgen Inc

* Amgen and AbbVie agree to settlement allowing commercialization of Amgevita

* Amgen Inc - Amgen expects to launch Amgevita in Europe on Oct. 16, 2018, and Amjevita in United States on Jan. 31, 2023.​

* Says to begin launching biosimilar adalimumab in Europe in 2018​​

* Amgen Inc - ‍under terms of agreement, AbbVie will grant patent licenses for use and sale of Amgevita/Amjevita worldwide, on a country-by-country basis​

* Says Amgen and AbbVie have agreed to dismiss all pending litigation​

* Says ‍specific financial terms of agreement were not disclosed​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below